Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly Announces New Drug Discovery Initiative
Eli Lilly has announced that it will be initiating drug discovery in new and unmet diseases, which includes Alzheimer’s disease, Cancer, Diabetes and Osteoporosis. The company’s goal is
Eli Lilly has announced that it will be initiating drug discovery in new and unmet diseases, which includes Alzheimer’s disease, Cancer, Diabetes and Osteoporosis. The company’s goal is
Canada-based AEterna has reported that patient follow-up in the safety study of its phase-III program in benign prostatic hyperplasia (BPH) with its endocrinology compound, cetrorelix pamoate, is scheduled
New York-based NeoStem has announced that it has signed an exclusive 10 year agreement with Enhance BioMedical, a Shanghai-based company, to develop a Stem Cell Collection and Treatment
California-based, Proteolix has announced that selective immunoproteasome inhibitor PR-957 was shown to block disease progression in rheumatoid arthritis in a dose dependent manner, and completely eliminate visible signs
GlaxoSmithKline has signed an agreement with Dr. Reddy’s to develop and market selected products across an extensive number of emerging markets, excluding India. Under the terms of the
Synta, a biopharmaceutical company and GlaxoSmithKline have decided to end the collaborative agreement for the clinical development and commercialization of elesclomol, effective no later than September 10, 2009.
Canada-based QLT has announced 12-month primary analysis results from the Novartis sponsored phase-II Mont Blanc study . Mont Blanc is the European study of the Novartis sponsored Summit
Sinovac, China-based developer and provider of vaccines, has declared that it has completed the construction of the H1N1 virus seed bank necessary to produce a virus antigen. Sinovac
Boehringer Ingelheim and Vitae have announced that they have entered into a worldwide collaboration to research and develop beta-secretase (BACE) inhibitors, for the treatment of Alzheimer’s disease. Under
California-based pharmaceutical company, Transdel has announced that it anticipate reporting top-line results from its current phase-III study of Ketotransdel during the third quarter of 2009. The phase-III study